Processa Pharmaceuticals Reports FDA Clearance for VT-7208 Phase 2 Study

Processa Pharmaceuticals reported FDA clearance for a Phase 2 study of VT-7208, a new pipeline collaboration and the appointment of Sheila Gujrathi as Executive Chair.